Zydus Cadila's Baddi plant gets USFDA approval

NEW DELHI: Drug firm Zydus Cadila today said the American health regulator, US Food and Drug Administration (USFDA), has given the green signal for commencement of drug supplies to the US from its formulations plant at Baddi, Himachal Pradesh.

With the approval in place, the plant -- which currently caters to domestic and emerging market requirements -- will commence supplies to the US, Zydus Group said in a statement.

Commenting on the development, Zydus Cadila CMD Pankaj R Patel said: "The USFDA approval for the Baddi plant enables us to open up an additional resource to cater to the growing needs of our US business."

The company's Baddi plant was commissioned in 2004 and manufactures oral solid dosage medicines, including hard gelatin capsules and tablets.